Vnitr Lek 2024, 70(6):399-402 | DOI: 10.36290/vnl.2024.078

Semaglutide in different indications

Ľubica Cibičková
Diabetologické centrum, 3. interní klinika, Fakultní nemocnice Olomouc
Interní a diabetologická ambulance AIDIN VK s.r.o., Hranice

Semaglutide belongs to the group of GLP-1 receptor agonists, which have a significant effect on the adjustment of blood sugar and body weight. The development of semaglutide administration led to subcutaneous administration once a week and orally once a day. This article provides information on current indications for semaglutide treatment, as well as contraindications and side effects. Finally, the use of semaglutide as an antiobesity drug is mentioned.

Keywords: semaglutide, diabetes mellitus type 2, GLP-1 agonists.

Accepted: September 19, 2024; Published: October 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cibičková Ľ. Semaglutide in different indications. Vnitr Lek. 2024;70(6):399-402. doi: 10.36290/vnl.2024.078.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Haluzík R. Semaglutid. Remedia. 2019;26:25-31. Go to original source...
    2. Račická E. Současné možnosti léčby diabetes mellitus 2. typu pomocí agonistů GLP-1. Farmakoter Revue. 2019;4(1):74-82.
    3. Rasmussen MF. The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. Diab etol Int. 2020 Jan 4;11(2):76-86. Go to original source... Go to PubMed...
    4. Račická E. Semaglutid - první perorální agonista receptorů GLP-1 a jeho postavení v léčbě diabetu. Farmakoter revue. 2022;7(1):51-56.
    5. Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020 Nov;229:61-69 Go to original source... Go to PubMed...
    6. Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022 Jan;134(sup1):5-17. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.